Introduction
Autografting for patients with chronic lymphocytic leukemia (CLL) has increased significantly over the past few years. 1 Owing to the improvements of supportive therapy, the transplantrelated mortality in this setting is now below 10%. However, contamination of bone marrow (BM) and peripheral blood (PB) by residual leukemic cells may preclude the success of this procedure, and the event-free survival curve shows a steady decline because of relapse occurring for years after transplantation. Among predictors of response and outcome after transplantation, the status of the disease before transplantation emerges as very important in most series (von Neuhoff et al. Blood 1998; 92: 652a, abstract). 2 These results suggested that the purging of minimal residual disease (MRD) is critical for the outcome of autografted patients with CLL. To achieve this goal, targeted approaches with monoclonal antibodies have been explored. Alemtuzumab (Campath-1H) is a genetically reshaped human IgG1 antibody directed against CD52, an antigen expressed at high levels on most normal and malignant mature lymphocytes, but not on hemopoietic stem cells. 3, 4 Preliminary data indicate that treatment with fludarabine (FAMP) for debulking and Campath-1H to purge residual disease is capable of eradicating CLL to levels that are undetectable by flow cytometry or polymerase chain reaction (PCR). 5 With respect to the ability to mobilize sufficient PB progenitor cells (PBPCs) after purine analogues, there are conflicting data mainly depending on the disease status and the number of previous treatment attempts. [6] [7] [8] However, there are only few data about PBPC collection after Campath-1H. 9 Optimizing PBPC collection remains a crucial point not only to increase the proportion of patients who can proceed to autologous stem cell transplant (ASCT) but also for other reasons: to reduce the time to hematopoietic recovery posttransplant; to maximize the efficiency of the PBPCs collection process given the morbidity and costs of apheresis; and to reduce the need for second mobilizations and BM harvests. Although randomized studies have not been performed, more CD34 þ cells are collected following chemotherapy and a growth factor than following current usage of a growth factor alone. 10, 11 However, the collection of PBPCs following chemotherapy and a growth factor may be associated with significant morbidity, expense and inconvenience in scheduling apheresis procedures. While a wide variety of regimens have been employed, the combination of cyclophoshamide (CTX) 4À7 g/m 2 is the most commonly used. 12 Ara-C has been extensively employed as a mobilization regimen for acute leukemia mainly using a high dose (1.5-2.0 g/m 2 ). 13 To our knowledge, there are no reports of priming attempts with intermediate-dose Ara-C (ID Ara-C) in CLL. The rationale of using ID Ara-C for mobilization in our study was based on the observations that the drug at high doses proved to be highly effective in PBPC harvesting and in vivo purging in indolent lymphomas, 14 and that it demonstrated some cytoreductive efficacy in CLL. [15] [16] [17] Furthermore, ID Ara-C has not been included in any phase of our debulking CLL program and in our conditioning regimen for ASCT.
The aims of the present study were: (1) to verify the feasibility of PBPCs collection after a sequential program of treatment with FAMP and Campath-1H; (2) to determine whether granulocyte colony-stimulating factor (G-CSF) as a single agent, initiated during steady state, was able to mobilize PBPCs; (3) to assess whether in patients failing adequate mobilization after G-CSF alone priming with ID Ara-C plus G-CSF could allow a successful CD34 þ yield; and (4) to assess the safety profile of ID Ara-C as priming chemotherapy in this particular setting of patients. 19 The median number of courses administered was 6 (range 4-13). Indeed, one patient received eight courses of FAMP alone as first line followed by five courses of FAMP plus CTX for recurrent disease 15 months after the previous treatment. Courses were repeated every 4-6 weeks depending on the recovery of counts, with courses being delayed until the platelets were more than 100 Â 10 9 /l and the WBC was more than 3 Â 10 9 /l. Patients in partial remission (PR), PR nodular (PRn) or in complete remission (CR), 18 without the disappearance of the molecular aberration (IgH monoclonal expression), received Campath-1H (supplied by Ilex Oncology, Guilford Sussex, UK) subcutaneously (s.c.), thrice a week for 6 weeks, in escalating doses up to 10 mg.
Materials and methods

Patients
Campath-1H was given at least 8 weeks after the discontinuation of FAMP. The median time from FAMP discontinuation to Campath-1H was 5 months (range 2-11 months). Subcutaneous administration was chosen, as this route produces the fewest side effects. 5, 20 The administration of Campath-1H after FAMP carries the danger of immunosuppression, since both drugs are toxic to T lymphocytes. In normal individuals, the T cells provide a 'sump' to absorb quantities of the monoclonal antibody; following FAMP treatment this 'sump' is no longer present, so that in theory less antibody will be required for the same effect. Furthermore, the lower dose is justified by the status of residual disease, which characterizes the patients in our study. These conditions could represent the background to reduce the dose of Campath-1H from the conventional dose of 30-10 mg.
Disease restaging, performed after completion of treatment with the purine analogue and after Campath-1H included BM aspiration, trephine biopsy, immunophenotyping, molecular study for IgH rearrangement. An immunophenotyping panel, including CD5, CD19, CD20, CD22, CD23, CD38, CD79b, FMC7 and surface Ig light chains, was used in quadruple color flow cytometric combinations with directly labelled antibodies (BD Biosciences, San Jose', CA, USA) similar to that described by Rawstron et al. 21 Residual B-CLL cells were defined by a stepwise logical gate analysis, where the fluorescence pattern of abnormal B-cell coexpressions CD19, CD5, CD23 and CD79b was clearly discriminated from their normal counterpart (ie B-
neg , CD237, CD79b þ þ ). Moreover, the cells falling into the fluorescence capture gate were backgated into an FSC/SSC diagram to gate out cell debris and nonspecifically stained events.
The PCR method for the Ig heavy-chain gene used an Fr2 or Fr3 V-region primer in conjunction with nested primers directed to the J region. The sensitivity of PCR assay is able to detect a single CLL cell in up to 10 5 normal leukocytes. 22 All patients were submitted to ultrasound of the abdomen and standard radiography of the thorax, while computed tomography scanning of abdomen and thorax was carried out only in selected cases.
Mobilization regimens
In the first 10 patients, the mobilization regimen consisted of G-CSF alone started at least 8 weeks after completion of Campath-1H. Patients received an initial dose of G-CSF (filgrastim) 5 mg/ kg/die subcutaneously. An increase to 10 mg/kg/die was made in eight patients as after 5 days the measurement of PB CD34 þ cells did not reach the threshold of 10/ml. Growth factor was interrupted if a decrease of CD34 þ cells count was recorded. The optimal timing of the leukaphereses (LPs) was guided by the blood CD34 þ cell count. Patients who did not achieve the target of 2.5 Â 10 6 CD34 þ cells/kg after three collections were considered to be eligible for a second strategy of PBPCs mobilization. Among the 10 poor mobilizers with G-CSF alone, two patients had received FAMP orally while in the remaining eight patients FAMP was administered i.v.
Fourteen patients, eight failing mobilization with the growth factor alone and the last six patients entering our study, received as priming ID Ara-C, 800 mg/m 2 /q12 h for six doses followed by G-CSF at a dose of 5 mg/kg/day s.c. as of the first day after Ara-C to the end of harvesting. Aphereses were planned during the CD34 þ cells priming with ID Ara-C after chemo-immunotherapy in CLL M Montillo et al recovery phase following ID Ara-C-induced aplasia. The median time between the attempt with G-CSF alone and the second attempt with ID Ara-C þ G-CSF in eight patients was 4.5 months (range 1-6 months). White blood cells and platelets counts were monitored daily using automated counters. Irradiated prophylactic platelet and red blood cell transfusions were administered when the platelets count was less than 10 Â 10 9 /l or less than 20 Â 10 9 /l in febrile (4381C) patients, and the hemoglobin level less than 8 g/l. During marrow aplasia, ciprofloxacin 500 mg twice/day and itraconazol 30 ml oral solution once/day were administered as prophylaxis of bacterial and fungal infections.
Toxicities following ID Ara-C priming therapy were evaluated according to NCI criteria. 23 
Collection of progenitor cells and quality assessment
Daily measurements of PB CD34 þ cells were performed from the third day when patients received G-CSF alone or after 10 days from the completion of ID Ara-C priming therapy.
Peripheral CD34 PBPC assay was accomplished according to ISHAGE Protocol adapted for single-platform flow cytometric analysis. 24 LPs were started when this count reached X10/ml and were continued daily until enough cells were collected to ensure the reinfusion of X2.5 Â 10 6 /kg CD34 þ . LPs was performed with continuous-flow blood cells separator Cobe Spectra 3000. The total volume processed in each LP was between two and three blood mass volumes at a flow rate of 40-70 ml/min. The percentage of CD34 þ cells was determined using a three-cytometric parameter assay on a FACScalibur (Becton Dickinson). The clonogenic assays for CFU-GM was performed by plating 10 000 TNC/ml from LP product in GF 4534 Methocult (Stem Cell Technologies, Vancouver, Canada) with EPO addition (3 U/ml). The LPs products were also analyzed by flow cytometry for CD19 þ /CD23 þ /CD5 þ / CD79b þ cells and by PCR for the IgH rearrangement. Table 1 shows the disease status after chemo-immunotherapy at the time of mobilization. All but two patients were in complete morphologic and immunophenotypic remission, eight of them presenting a polyclonal rearrangement of IgH. Two patients were in partial nodular remission.
Results
Results of mobilization with G-CSF alone
In the 10 patients receiving G-CSF for mobilization, median time from the last dose of FAMP to G-CSF was 8.5 months (range 5-19 months), while 2 months (range 2-4 months) was the median time from last Alemtuzumab administration to the G-CSF priming. The growth factor was administered for a median of 8 days (range 7-9 days).
As shown in Figure 1 , PBPCs collection after G-CSF alone was considered to be successful in two out of the 10 patients, the harvesting product being 3.4 and 3.2 Â 10 6 /kg CD34 þ cells, respectively. In both cases, a suitable product was obtained after three LPs with G-CSF given for 7 and 8 days. The median number of total nucleated cells and CFU-GM are reported in Table 2 . The two patients were both in CR after chemo-immunotherapy with BM showing a polyclonal IgH rearrangement in one case and monoclonal in the other case; the same result was obtained when the IgH rearrangement was analyzed in the products of LPs. The percentage of CD19 þ , CD5 dim , CD23þ þ , CD79bþ cells identified in the PBPC was o1% in both cases ( Table 2) .
In four cases, the minimum threshold of X2.5 Â 10 6 /kg CD34 þ cells was not reached after a median number of three LPs (range 1-4). The median number of CD34 þ cells collected in this group of patients was 0.95 Â 10 6 /kg (range 0.29-2.2). In all cases, apheresis procedures were interrupted because of the decrease in the number of CD34 þ cells/ml.
Figure 1
PBPCs collections after G-CSF alone and after intermediate dose Ara-C þ G-CSF in CLL patients treated with sequential fludarabine and Campath-1H.
Table 2
Results of harvesting after G-CSF alone and after ID Ara-C+G-CSF in 15 CLL patients treated with sequential fludarabine and Campath-1H
Harvest after G-CSF harvest after ID Ara-C+G-GSF 
CD34 þ cells priming with ID Ara-C after chemo-immunotherapy in CLL M Montillo et al
In the remaining four patients, the PBPCs collection was not performed because the peripheral CD34 þ cells count did not reach the threshold of X10/ml. after a median number of 8 days (range 8-9 days).
Results of mobilization with ID Ara-C and G-CSF
The eight patients who failed the PBPCs collection with the growth factor alone plus six patients who were not previously primed with G-CSF underwent mobilization chemotherapy with ID Ara-C. The median time interval between the last dose of FAMP and the administration of Ara-C was 9.5 months (range 7-28 months), while the median time from last Campath-1H and the beginning of Ara-C was 5 months (range 2-9 months). In the six patients directly submitted to ID Ara-C priming, the time elapsed from the completion of FAMP treatment and ID Ara-C was 8 months (range 7-28 months), while time interval since Campath-1H was completed and mobilizing chemotherapy was 4.0 months (range 2-5 months). In one patient in PNR at the time of priming, collection was not performed because the peripheral CD34 þ cells count did not reach the threshold of X10/ml. This patient showed a hypoplastic phase lasting longer than 12 months after the fifth course of FAMP as first-line treatment. The median number of CD34 þ cells collected was 18 Â 10 6 /kg (range 10-62.3), all patients having X10 Â 10 6 /kg CD34 þ cells. Aphereses began between days þ 12 and þ 14 from the end of chemotherapy; a median number of one LPs was performed (range 1-2).
The median number of total nucleated cells and GM-CFU according to the type of priming are reported in Table 2 .
As far as the impact of i.v. vs oral FAMP on PBPCs mobilization and toxicity is concerned, we did not record any difference between the two routes of administration of this drug.
Before ID Ara-C priming, 12 patients were in CR, six showing a polyclonal IgH rearrangement, while two patients were in PRN both with a monoclonal IgH rearrangement. PCR performed on the product of leukapheresis in the 13 patients in whom a suitable product was obtained showed a monoclonal IgH in six cases and polyclonal in the remaining seven cases. A leukapheretic product with polyclonality was obtained in all but one patient showing polyclonal IgH rearrangement in the BM before treatment with Ara-C and in three patients showing a monoclonality before priming with chemotherapy. The median percentage of CD19 þ , CD5 dim , CD23 þ þ , CD79b þ cells identified in the PBPCs was 0.8% (range 0-4.3).
Toxicity after treatment with ID Ara-C As regards hematological toxicity, all patients experienced neutropenia considered as PMN p1.0 Â 10 9 /l, and thrombocytopenia considered as platelet counts (PLT count p20 Â 10 9 /l). The median duration of neutropenia was 7 days (range 5-13 days); 9 days was the median duration (range 5-9 days) of severe thrombocytopenia.
Prophylactic platelet transfusions were administered to all but one patient; the median number of single donor platelet units transfused was 3 (range 1-8). Six patients required RBC transfusions, but only three of them required more than one unit.
During marrow aplasia, seven patients experienced an episode of fever X38.51 not lasting usually more than 1 day (range 1-7 days); all the seven patients received intravenous empiric broad-spectrum antibiotic therapy. In one patient fever was related to sepsis sustained by Escherichia coli, in the remaining six it was of unknown origin.
Patients were discharged at the end of chemotherapy and readmitted when they became neutropenic (o1000/ml). The median time spent in the hospital for the aplastic phase monitoring and the apheretic procedure was 10 days (range 9-11 days).
No other type of extrahematological toxicity was recorded.
Patients submitted to ASCT
Up to now six patients have been submitted to ASCT, and the median follow-up is 8 months from transplant (range 2-16 months). The conditioning regimen consisted in CTX plus total body irradiation in three cases and high-dose Melphalan in the remaining three. The median time to recovery of PMN X500/ml was 9 days (range 8-10 days), while the median time to recovery for PLT X20 000 ml was 10 days (range 9-12 days). No infections were recorded before the recovery and no opportunistic infections have been detected during the observational period after the procedure. All patients are alive in CR according to NCI WG criteria.
Discussion
Although CLL is considered an incurable disease using a standard dose of chemotherapy, it is characterized by chemosensitivity at least early in the clinical course, making investigation of the role of chemotherapy dose escalation interesting in this disease. Considering the long natural history of CLL to verify the curative intent of ASCT procedure means that very long-term follow-up is required. Therefore, investigators have been examining whether laboratory analyses might provide surrogate measurements that will be useful to predict which patients are likely to relapse. 2 Considerable attention has been focused on the significance of MRD as a surrogate for subsequent relapse.
A number of techniques can be used to increase the sensitivity of MRD detection in patients with CLL. The most sensitive widely employed techniques are flow-cytometric assay and PCR analysis. Flow-cytometric assay has sensitivity comparable with PCR, but is readily quantitative and rapid. The clinical usefulness of PCR detection of MRD after ASCT has previously been suggested for indolent lymphomas by studies of DanaFarber Cancer Institute. 2 Persistence of MRD was associated with increased probability of relapse.
Fludarabine has been established as an effective agent that produces a higher CR rate compared with traditional chemotherapy in randomized trials. 25, 26 However, there was no evidence that fludarabine improves survival times, 27 and the median time to progression for responders to FAMP was 31 months. 28 Targeted therapy with monoclonal antibodies of different specificity has been used in lymphoid malignancies. In the likelihood of therapeutic success, the nature of the target antigen plays an important role. An antigen such as CD52 is nonmodulating, therefore therapeutic efficacy is elevated. CD52 is permissive for lysis with both effector cells and complement, so that Campath-1H may be an ideal agent in CLL. Preliminary results have been published showing the ability of Campath-1H to eradicate CLL to levels that are undetectable by flow cytometry or PCR 5, 9 leading to the best collectable product for a transplantation procedure. In younger patients with CLL, the experience of ASCT is increasing. There have been, however, some anecdotal reports of poor mobilization after FAMP precluding the ASCT procedure in such patients. 6, 7 As CD52 antigen is not expressed in hematopoietic progenitors, immunotherapy with Campath-1H should not reduce the ability to collect stem cells. However, only few data are at present available about PBPC collection in patients treated with FAMP and Campath-1H. 9 In our series, we were able to collect peripheral stem cells in all but one patient (93.7%) after the sequential administration of FAMP and Campath-1H. There is a considerable debate regarding the superior hematopoietic progenitor cell mobilization after chemotherapy and G-CSF or GM-CSF compared with growth factors alone. 29 Furthermore, increasing the dose of G-CSF to 10 mg in the eight poor mobilizers proved to be an unsuccessful measure. The results from our study are consistent with this observation, with higher number of successful harvesting after the combination (13/14 patients) compared with G-CSF alone (2/10 patients). The safety profile of ASCT procedure is strictly related to the quantity of CD34 þ cells reinfused. 30 ID Ara-C in our series allowed either mobilization in a higher number of cases and collections of larger amount of CD34 þ cells (18 Â 10 6 /kg) compared with G-CSF alone (3.3 Â 10 6 /kg). Moreover, we found a larger amount of CFU-GM yield in PBPCs collections after ID Ara-C (median 371.3518 Â 10 4 /kg) rather than in the harvests of the two patients successfully mobilized after the growth factor alone. Resource utilization measures such as the number of apheresis sessions required for target PBPCs collection, length of hospital stay and transfusions required are all important issues in a costeffectiveness analysis. Only patients who received chemotherapy were admitted to the hospital; they were discharged at the end of treatment and readmitted when they became neutropenic in order to reduce the time length of hospitalization. The median number of apheresis sessions was very low when patients received combination compared to G-CSF alone.
Our program was initially planned to verify the ability of G-CSF alone to prime PBPCs. Actually, PBPC collection after 4-5 days of G-CSF is easy to schedule and it is unlikely that the sessions have to be delayed or cancelled because of complications. However, facing the high proportion of unsuccessful attempts and even increasing the dose of the growth factor, we decided on a second chance using ID Ara-C as a primer. The interpatient variability after recovery of ID Ara-C was not problematic, with the majority of patients collecting after 12 days from the completion of treatment. The use of chemotherapy has the potential for reducing contamination of the harvested PBPCs, although increased mobilization of tumor cells has also been reported. 31, 32 An increased cumulative proportion of harvesting free of lymphoma cells after high-dose Ara-C in a program of sequential high-dose therapy conducted in patients with mantle cell and indolent lymphomas has recently been recorded.
14 In comparison to patients primed with high-dose CTX, ID Ara-C þ G-CSF gave mobilization in a higher proportion of cases with greater collections of CD34 þ cells/kg. 33 The longer time lapse between Campath-1H to ID Ara-C compared to the time interval between Campath-1H to G-CSF alone could have played a role in the ability of mobilization. However, it is worth noting that no difference in time interval between the last dose of FAMP and priming was recorded between the group that received only ID Ara-C as priming and patients who underwent both attempts of collections. Moreover, it seems that no role was played by the marrow reserve in patients with less advanced disease considering that both patients who collected X2.5 Â 10 6 /kg CD34 þ with G-CSF alone were in stages III-IV according to Rai staging system. Finally, no difference in the amount of CD34 þ cells collected was observed between the patients who performed both attempts of collections compared with patients who received only ID Ara-C. The only patient unable to mobilize CD34 þ cells showed a long-lasting pancytopenia after FAMP treatment as first line. Although cytoreductive efficacy of ID Ara-C in CLL has been demonstrated when used in combination, 17 the drug alone has been investigated only in few poor prognosis cases with disappointing results concerning the antileukemic effect. 16 However, as already mentioned the in vivo purging efficacy of high-dose Ara-C has been reported in patients with mantle cell and indolent lymphomas. 14 In our study, three patients switched from a monoclonal rearrangement for IgH gene to polyclonal collections after ID Ara-C þ G-CSF mobilization, and three patients switched from a polyclonal rearrangement for IgH gene to a monoclonal collection after ID Ara-C þ G-CSF. One concern with the use of chemotherapy for mobilization is the morbidity. In our series, the extrahematologic toxicity was manageable with only one patient showing a sepsis and no evidence of opportunistic infections.
In conclusion, our study demonstrated that the successful collection of PBPCs is achievable in CLL patients treated with sequential FAMP and Campath-1H with a priming including ID Ara-C þ G-CSF. In our experience, G-CSF employed alone in 10 patients was unable to mobilize PBPC in four and gave insufficient collections for a transplant in four other cases. ID Ara-C þ G-CSF proved to be able to mobilize PBPCs in a high proportion of cases (92.8%) obtaining a large amount of CD34 þ cells/kg with a manageable hematological and extrahematological toxicity.
